Zyngenia, a Gaithersburg, Md.-based biopharmaceutical company developing next-generation multi-specific antibody-based drugs, has appointed Frank Hsu, M.D., as chief medical officer and a member of its executive team.
Prior to joining Zyngenia, Hsu served as senior medical director at Genzyme in the transplant and oncology division. For over nine years, he was responsible for the clinical development of products in the areas of hematology, oncology and stem cell transplant. In addition to his support of commercial products, Hsu actively provided medical support related to business development, strategic planning, partnership management, medical affairs, and corporate acquisitions.
Hsu also currently serves on the board of trustees of the Grunebaum Cancer Research Foundation.